Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
A phase 3 trial of Nogapendekin alfa inbakicept, Tislelizumab and Docetaxel in non-small-cell lung cancer, run by ImmunityBio, Inc., now recruiting.
Overview
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In is a phase 3 interventional study registered as NCT06745908 by ImmunityBio, Inc., with 507 participants planned, started 2025-10-01 and due to reach its primary completion in 2028-09. Interventions recorded: N-803, Tislelizumab, Docetaxel and Prior failed checkpoint inhibitor.
Similar pages
not linked directly; found by shared links- TrialN-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
- TrialCombination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
Shares Tislelizumab, Docetaxel and the tag pipeline.
- TrialA Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Shares ImmunityBio and the tag pipeline.
- TrialStudy of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Shares ImmunityBio and the tag pipeline.
- TrialA Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Shares Tislelizumab and the tag pipeline.
- TreatmentCD19 t-haNK
Shares ImmunityBio and the tag pipeline.